RESEARCH Open Access

Monocyte lymphocyte ratio, IL 6, and their association with increased carotid intima-media thickness as simple predictive markers for nephropathy in Egyptian diabetic patients

Heba Mahmoud Mohamed Ibrahim^{1*}, Heba Morad Bahgat¹, Deena Ahmed Sharshar¹ and Tarek Abdel Azim Ramzy²

Abstract

Background Inflammation is a cardinal mechanism of diabetic kidney disease (DKD). Interleukin-6 (IL6) is a reliable indicator that plays a role in the progression of DKD. Monocyte-to-lymphocyte ratio (MLR) is also implicated in this inflammatory process. The progression of DKD is associated with increased carotid intima-media thickness (CIMT), which is an independent predictor of atherosclerosis.

Aim The role of IL6 and MLR ratio influencing the progression of DKD was assessed using the urinary albumin creatinine ratio (UACR) and glomerular filtration rate (GFR). Moreover, their contribution to increasing CIMT in DKD was assessed.

Methods An observational prospective study was conducted on ninety diabetic patients presented to the Internal Medicine Clinic at Kasr AlAiny. The subjects were classified into three groups, thirty patients for each, according to UACR: with normoalbuminuria, microalbuminuria, and macroalbuminuria. A history and clinical assessment, CBC, MLR, HbA1c, lipid profile, IL6, creatinine, and eGFR were carried out. Furthermore, CIMT was measured using Doppler ultrasound.

Results The results showed that IL6 and MLR were significantly higher in the macroalbuminuria group compared to the other two groups with p < 0.001, suggesting that their higher level could predict the progression of DKD. According to the ROC curve, the cutoff values of MLR and IL6 were 0.3425 and 7 pg/ml, respectively. Moreover, CIMT increased significantly in micro and macroalbuminuric patients with p > 0.001. IL6 and MLR were positively correlated with CIMT in micro and macroalbuminuric patients.

Conclusion Both MLR and IL-6, as simple biomarkers associated with increased CIMT, play an important role in predicting the nephropathy of DKD patients.

Keywords DKD, Albuminuria, eGFR, MLR, IL-6, CIMT

drbebo88@gmail.com

Introduction

Diabetic kidney disease is one of the most prevalent major causes of renal disease that progresses to end-stage kidney disease and necessitates ongoing hemodialysis [1]. Thus, the early detection of the risk for diabetes and microvascular complications offers a chance to implement prophylactics to halt or postpone the onset of the



^{*}Correspondence: Heba Mahmoud Mohamed Ibrahim

¹ Internal Medicine Department, Kasr Al Ainy Hospital, Cairo University,

² Clinical Pathology, Kasr Al Ainy Hospital, Cairo University, Cairo, Egypt

disease and its progression. Interleukin (IL)-6 is a proinflammatory cytokine secreted by all types of kidney cells, podocytes, and mesangial cells, as well as endothelial and epithelial cells [2]. It can stimulate the release of other cytokines [3]. So IL-6, as a significant inflammatory mediator, is thought to be involved in the pathophysiology of DKD [4]. Furthermore, low lymphocyte counts and high monocyte counts have been used as inflammatory markers in several studies, and it has been suggested that they may be used in the diagnosis or estimation of prognosis in inflammatory states for DKD patients [5].

Diabetes is well known to be a risk factor for atherosclerotic diseases. So, CIMT measurement permits the early identification of arterial wall atherosclerotic lesions [6]. To promote atherogenesis, IL-6 is reported to stimulate monocyte chemoattractant protein 1 secretion from macrophages [3] and is associated with the increased expression of cell adhesion molecules [7]. Moreover, it was discovered that increased MLR resulted in an imbalance in innate and adaptive immunity. This imbalance may be the main cause of increased CIMT and atherosclerotic plaque formation [8].

Objectives

The aim of this study is to detect the role of MLR as a marker of inflammation and IL6 as a proinflammatory cytokine, which are associated with the development and progression of DKD assessed by UACR and eGFR. Additionally, assessing the impact of elevated levels of IL 6 and MLR on CIMT in DKD patients.

Methods

Our observational prospective study was conducted on ninety diabetic patients presented to our Internal Medicine Clinic at Kasr Al-Ainy from December 2022 to July 2023. Based on UACR, the subjects were divided into three groups: thirty diabetic patients for each group: normoalbuminuria (<30) (without nephropathy), microalbuminuria (30-300), and macroalbuminuria (>300). In accordance with current KDIGO guidelines 2020, CKD is defined as persistently elevated urine albumin creatinine excretion (≥30 mg/g, persistently reduced estimated glomerular filtration rate (eGFR < 60 ml/min per 1.73 m²), or both for 3 months. Patients were fully informed about the research plan, and consent was obtained from every patient. A full history was taken for each subject, and a clinical assessment was carried out. UACR, complete blood count with an assessment of MLR, HbA1c, lipid profile, serum creatinine, and GFR were calculated by the chronic kidney disease epidemiology collaboration (CKD EPI) equation, and IL6 was conducted. Type II diabetic patients with an average age of 40-60 years and normal thyroid function met the inclusion criteria. Patients with uncontrolled hypertension, smokers, or those with autoimmune, cancer, infection, or inflammatory conditions were excluded.

A Philips ultrasound system with a 5–10-MHz multifrequency high-resolution linear transducer (L9-12) was used to perform automated measurements of CIMT in mm. The measurements were carried out in the longitudinal section of the common carotid artery (CCA). CIMT was measured at a distance of at least 5 mm below the distal end of CCA before the carotid bifurcation [9] with the subject lying down, neck extended and head slightly turned in the direction opposite to the carotid artery being examined at the posterior wall, along an axis perpendicular to the artery, to establish a line from the intima to media interface. The averaged CIMT of the maximum value on both sides was calculated as follows: CIMT = (Right-CIMT + Left-CIMT)/2.CIMT between 0.5 and 0.8 mm were considered to be within the normal range [10] (Fig. 1). The approval number of the ethical committee was MS-261-2022.

Statistical analysis

According to this equation for calculating the sample size: Qualtrics= $(Zscore)2 \times StdDevx(1-StdDev)/(margin of error)2$. After converting the confidence level to the Z score, assuming a confidence level of 95%, the Z score=1.96, and a margin of error (confidence interval) of 10%. Therefore, the final sample size was 96 participants.

Data were coded and entered using the Statistical Package for the Social Sciences (SPSS) version 28 (IBM Corp., Armonk, NY, USA). They were summarized using mean and standard deviation for normally distributed quantitative variables or median and interquartile range for non-normally distributed quantitative variables and frequencies (number of cases) and relative frequencies (percentages) for categorical variables. Comparisons between groups were made using analysis of variance (ANOVA) with multiple comparisons post hoc test in normally distributed quantitative variables, while non-parametric Kruskal-Wallis test and Mann-Whitney test were used for non-normally distributed quantitative variables [11]. The chi-square ((2) test was performed to compare categorical data. The exact test was used when the expected frequency was less than 5 [12]. Correlations between quantitative variables were conducted using the Spearman correlation coefficient [13]. The receiver operating characteristic curve (ROC curve) was constructed with the area under curve analysis performed to detect the best cutoff value of IL-6 and MLR to detect albuminuria. P-values less than 0.05 were considered statistically significant.



Fig. 1 Measurement of CIMT

Table 1 Demographic data of the studied groups

| | Normoalbuminuric group Count | Microalbuminuric group Count | Macroalbuminuric group Count | <i>P</i> -value |
|--------|------------------------------------|------------------------------------|------------------------------------|-----------------|
| Sex | | | | |
| Female | 16 | 17 | 18 | 0.873 |
| Male | 14 | 13 | 12 | |

Results

The study was performed with 96 diabetic patients, but six patients were excluded due to suspected underlying malignancy and infection. The number of female patients was 16 in the normoalbuminuric group, 17 in the microalbuminuric group, and 18 in the macroalbuminuric group. The number of male patients was 14 in the normoalbuminuric group, 13 in the microalbuminuric

group, and 12 in the macroal buminuric group. The analysis indicated no statistically significant difference in the distribution of sex and BMI among the three groups. The mean age was 49 in the normoal buminuric group, 51.27 in the microal buminuric group. It had no statistically significant difference among the three groups, with a P-value of 0.0531. The participant demographic distribution is presented in Tables 1 and 2.

LDL and TG mean was 72.76 mg/dl and 117.97 mg/dl, respectively, in the normoalbuminuric group, 84.63 mg/dl and 140.27 mg/dl, respectively, in microalbuminuric group and 113.50 mg/dl and 218.33 mg/dl, respectively, in macroalbuminuric group mg/dl. Both LDL and TG showed statistically significant differences among the three groups (p<0.001) (Table 2 and Fig. 2a, b). On the other hand, cholesterol showed no statistically significant difference

Table 2 Demographic data and laboratory data of the studied groups

| | Normoalbuminuric group | | Microalbui | Microalbuminuric group | | Macroalbuminuric group | | Effect size |
|-------------|------------------------|-------|------------|------------------------|--------|------------------------|---------|-------------|
| | Mean | SD | Mean | SD | Mean | SD | | |
| Age | 49.00 | 8.56 | 51.27 | 7.57 | 50.47 | 7.47 | 0.531 | 0.014 |
| BMI | 31.79 | 7.27 | 34.30 | 7.52 | 34.39 | 7.24 | 0.304 | 0.027 |
| Cholesterol | 184.93 | 36.56 | 190.47 | 39.99 | 207.87 | 52.25 | 0.109 | 0.050 |
| TG | 117.97 | 57.89 | 140.27 | 67.54 | 218.33 | 99.80 | < 0.001 | 0.243 |
| HDL | 50.33 | 19.82 | 53.70 | 17.08 | 49.97 | 28.01 | 0.772 | 0.006 |
| LDL | 72.76 | 34.05 | 84.63 | 28.44 | 113.50 | 52.48 | < 0.001 | 0.161 |
| HbA1C | 7.47 | 1.04 | 9.02 | 1.72 | 11.10 | 1.51 | < 0.001 | 0.521 |
| Creatine | 0.85 | 0.28 | 1.12 | 0.46 | 2.18 | 1.60 | < 0.001 | 0.266 |
| eGFR | 98.90 | 22.62 | 78.63 | 29.13 | 46.17 | 25.28 | < 0.001 | 0.423 |
| MLR | 0.25 | 0.14 | 0.26 | 0.16 | 0.48 | 0.15 | < 0.001 | 0.332 |
| IL6 | 4.81 | 7.16 | 16.74 | 7.74 | 29.40 | 5.74 | < 0.001 | 0.684 |




Fig. 2 a, b Comparison between the studied groups regarding triglycerides (TG) and LDL




Fig. 3 Comparison between the studied groups regarding HbA1c

among the three groups. Our study revealed that the HbA1C mean was 7.47 in the normoalbuminuric group, 9.02 in the microalbuminuric group, and 11.10 in the macroalbuminuric group. HbA1c was significantly elevated in the macroalbumiuric group compared to the normo and microalbuminuric groups (p < 0.001) (Table 2, Fig. 3).

Creatinine and eGFR mean were 0.85 mg/dl and 98.90 mL/min, respectively, in the normoalbuminuric group, 1.12 mg/dl and 78.63 ml/min, respectively, in the microalbuminuric group, and 2.18 mg/dl and 46.17 ml/min, respectively, in the macroalbuminuric group.

MLR and IL6 mean were 0.25 and 4.81 pg/ ml, respectively, in the normoalbuminuric group, 0.26 and 16.74 pg/ml, respectively, in the microalbuminuric group, and 0.48 and 29.40 pg/ml, respectively, in the macroalbuminuric group. Both MLR and IL6 showed a statistically significant difference in the macroalbuminuric group compared to the other two groups (p < 0.001) (Table 2, Fig. 4a, b).

CIMT mean measures among the three groups were 0.08 mm in the normoalbuminuric group, 0.64 mm in the microalbuminuric group, and 0.95 mm in the macroalbuminuric group, as shown in Table 3 and Fig. 5. It was significantly higher in the macroalbuminuric group than in the normoalbuminuric and microalbuminuria groups (p < 0.001).

As demonstrated in Tables 4 and 5, MLR exhibited a significant positive correlation with CIMT among micro and macroalbuminuric groups of DKD patients (*P*-value 0.045) in the microalbuminuric group and *P*-value 0.024 in the macroalbuminuric group. IL6 had a significant positive correlation with CIMT among micro and macroalbuminuric groups of DKD patients (*P*-value 0.021) in the microalbuminuric group and *P*-value 0.025 in the macroalbuminuric group (Fig. 6a, b).




Fig.4 a, b Comparison between the studied groups regarding MLR and IL6

Table 3 CIMT measures of the studied groups

| | Normoalbuminuric group | | Microalbuminuric group | | Macroalbuminuric group | | <i>P</i> -value |
|------|------------------------|------|------------------------|------|------------------------|------|-----------------|
| | Mean | SD | Mean | SD | Mean | SD | |
| CIMT | 0.08 | 0.01 | 0.64 | 0.17 | 0.95 | 0.12 | < 0.001 |




Fig. 5 Comparison between the studied groups regarding CIMT

MLR and IL-6 exhibited a significant positive correlation in diabetic patients with (P-value < 0.001), as shown in Table 6 and Fig. 7.

The ROC curve was constructed to assess the best cutoff values of MLR between the three studied groups. It revealed an AUC of 0.694 and a cutoff level of 0.3425, with a sensitivity of 58.3% and a specificity of 76.7%. On the other hand, the ROC curve described the best cutoff values of serum IL6 between the studied groups. It revealed an AUC of 0.929 and a cutoff level of 7 pg/ml, with a sensitivity of 93.3% and a specificity of 83.3%, as shown in Table 7 and Fig. 8.

Table 5 Correlation between MLR, IL 6, and CIMT with a total of ninety patients

| | | CILAT |
|------|-------------------------|---------|
| | | CIMT |
| CIMT | Correlation coefficient | 1.000 |
| | <i>P</i> -value | |
| | N | 90 |
| MLR | Correlation coefficient | 0.551 |
| | <i>P</i> -value | < 0.001 |
| | N | 90 |
| IL6 | Correlation coefficient | 0.760 |
| | <i>P</i> -value | < 0.001 |
| | N | 90 |

Discussion

In this study, we investigated the association between IL6 and MLR, which could be involved in multiple inflammatory pathways leading to the development of DKD and its progression. Albuminuria is considered an early stage for diabetic nephropathy.

Interleukin-6 (IL-6) is an important pro-inflammatory cytokine contributing to the onset and acceleration of microvascular and macrovascular complications in diabetes patients [14]. Overexpression of IL6 and its receptor can be mediated by podocytes, which may play a role in the development of various glomerular diseases. Moreover, Kim DI et al. found that elevated glucose induces IL-6 signal transduction and enhances IL-6 secretion in podocytes [15]. Furthermore, mesangial cells also have the ability to secrete IL-6, which stimulates the mesangial cells to produce monocyte chemoattractant protein 1,

Table 4 Correlation between MLR, IL 6, and CIMT among the groups

| | | Normoal buminuric group | Microalbuminuric group | Macroalbuminuric group |
|------|-------------------------|-------------------------|------------------------|---------------------------|
| | | CIMT | CIMT | CIMT |
| CIMT | Correlation coefficient | 1.000 | 1.000 | 1.000 |
| | <i>P</i> value | | | |
| | N | 30 | 30 | 30 |
| MLR | Correlation coefficient | 0.084 | 0.369 | 0.411 |
| | <i>P</i> value | 0.659 | 0.045 | 0.024 |
| | N | 30 | 30 | 30 |
| II6 | Correlation coefficient | 0.152 | -0.420 | -0.408 |
| | <i>P</i> value | 0.423 | 0.021 | 0.025 |
| | N | 30 | 30 | 30 |




Fig. 6 a, b Scatterplot showing a positive correlation between CIMT, MLR and IL6

Table 6 Correlation between MLR and IL 6

| | | MLR |
|-----|-------------------------|---------|
| IL6 | Correlation coefficient | 0.545 |
| | P-value | < 0.001 |
| | N | 90 |

which in turn increased monocyte recruitment and plays an important role in kidney injury [16]. Recently, it was found that IL-6 gene polymorphism is an independent risk factor for DKD in type II diabetic patients [17]. MLR is another inflammatory marker that was found to be a highly accurate predictor of diabetic nephropathy [14].




Fig. 7 Scatterplot showing a positive correlation between MLR and IL-6

| Table 7 Cuton value for the detection of proteinuna using it-6 and Mich | or the detection of proteinuria using IL-6 and | d MLR |
|-------------------------------------------------------------------------|------------------------------------------------|-------|
|-------------------------------------------------------------------------|------------------------------------------------|-------|

| | Area under the curve | P value | 95% confidence interval | | | | |
|-----|----------------------|---------|-------------------------|-------------|---------|---------------|---------------|
| | | | Lower bound | Upper bound | Cut off | Sensitivity % | Specificity % |
| MLR | 0.694 | < 0.001 | 0.587 | 0.801 | 0.3425 | 58.3 | 76.7 |
| II6 | 0.929 | < 0.001 | 0.865 | 0.993 | 7 | 93.3 | 83.3 |




Fig. 8 ROC curve for detection of the cutoff of IL6 and MLR

The current study revealed a statistically significant difference in IL6 levels and MLR among the three groups, which are significantly higher in the macroalbuminuria group compared to the other two groups with a (p-value < 0.001), suggesting that the rising levels of IL6 and MLR in the micro and macroalbuminuric group in diabetic patients may have an important role in the inflammatory process which are associated with development and DKD progression. To further evaluate the predictive value of MLR for DKD risk, a ROC curve analysis was carried out. As described earlier, the ROC curve illustrated the cutoff values of serum IL6 and MLR between the studied groups, which were 7 pg/ml and 0.3425, respectively Fig. 7 with a sensitivity of 58.3% and a specificity of 76.7% for MLR and a sensitivity of 93.3% and a specificity of 83.3% for IL6.

Our results agreed with Pham et al., who found a significant positive correlation between serum IL-6 and UACR in diabetic patients with UACR≥30 mg/g [18]. Furthermore, Akihiko et al. concluded that the level of IL6 was higher in participants with UACR>30 mg/g or

eGFR<60 mL/min/1.73 m² compared with those with UACR<30 mg/g or eGFR>60 mL/min/1.73 m²P<0.01 [19]. Similar to our study, Vaishya et al. found that the level of 24-h urinary protein was positively correlated with IL6 levels P<0.01 [20]. On the other hand, in support of the study of Kocak et al., who reported that MLR was significantly and positively correlated with the microalbuminuria group of DKD patients [14]. Also, Mehmet Z et al. suggested that MLR could be a predictive marker for DKD due to its strong positive correlation with microalbuminuria [5].

Microalbuminuria has been extensively regarded as a marker of endothelial dysfunction. There is also a pathophysiological mechanism linking albuminuria to atherosclerosis, which is related to its inflammatory role [21]. Our analysis emphasized the significant correlation between CIMT and albuminuria, and this result suggests that as DKD progresses from microalbuminuria to macroalbuminuria, there is a corresponding increase in CIMT. Ersin et al. observed a significant increase in CIMT in diabetic microalbuminuric patients with a *P*-value < 0.0001 [22].

In our study, the analysis showed a statistically significant difference in IL6 levels and MLR with increased CIMT in the microalbuminuric and macroalbuminuric groups compared to the normoalbuminuric group. Patients with increased CIMT had a higher level of IL6 and MLR, which may indicate an ongoing inflammatory process and a possible correlation with CIMT abnormalities. This coincides with the findings of Yu-qing et al., who found a positively correlated CIMT with IL-6 with a *P*-value < 0.001 [23]. According to Gong et al., MLR might be a more reliable predictor of atherosclerosis risk, identified early through CIMT evaluation [24]. Moreover, Sah Bandar et al. found that higher circulating monocytes were correlated with common carotid artery intima-media thickness [25].

Limitations

(I) Selecting patients who met these exclusion criteria was challenging. (II) Merely taking single measurements of MLR and IL6 may not be sufficient to detect variations in these parameters. (III) Anti-diabetic drug's effect on IL6 and MLR levels was not obviously detected.

Recommendations

As MLR and IL6 markers are simple and readily available, we recommend using them in daily practice, like the calculation of eGFR, as they might help in the early detection and follow-up of DKD patients to assess the ongoing inflammatory process of DKD which is associated with their higher level among DKD patients. Additionally, we recommend conducting studies with trials of anti-IL6 antibodies, which may halt the progression of DKD.

Conclusion

We suggest that MLR, IL6, and their association with increased CIMT could serve as a predictive marker for nephropathy in diabetic subjects due to its strong correlation with albuminuria. It may serve as an estimation of the underlying inflammatory burden that promotes nephropathy in diabetic subjects.

Abbreviations

MLR Monocyte-to-lymphocyte ratio

IL6 Interleukin-6

CIMT Carotid intima-media thickness

CCA Common carotid artery

CKD EPI Chronic kidney disease Epidemiology Collaboration equation

DKD Diabetic kidney disease

ROC curve Receiver operating characteristic curve UACR Urinary albumin creatinine ratio eGFR Estimated glomerular filtration rate

BMI Body mass index TG Triglycerides

KDIGO Kidney Disease: Improving Global Outcomes

Acknowledgements

I would like to acknowledge Dr. Mohamed Ashera, who contributed to providing us with a statistical analysis of this research.

Authors' contributions

Heba Mahmoud helped choose the research topic, used Doppler ultrasonography to evaluate CIMT, reviewed this study, wrote the discussion, and wrote this paper. Prof Heba Morad reviewed every detail in the study and made an effort to fix any mistakes. Dr Deena Sharshar contributed to collecting samples, contributed to writing the research, and played a role in funding this research. Prof Tarek Ramzy provided us with laboratory results.

Funding

The institution fund did not provide funding for this study. This research is funded by us.

Availability of data and materials

The datasets generated and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.

Declarations

Consent for publication

There was no individual person's data in any form (including individual details, images, or videos).

Competing interests

I, the corresponding author, confirm on behalf of all authors that there have been no involvements that might raise the question of bias in the work

reported or in the conclusions, implications, or opinions stated. We have no conflict of interest to disclose.

Received: 28 December 2023 Accepted: 30 January 2024 Published online: 13 February 2024

References

- Soliman D, Ibrahim D, Abass M (2021) Changes in kidney function (GFR), albuminuria, electrolytes, and heart affection in diabetic chronic kidney disease patients. The Medical Journal of Cairo University 89(December):2923–2933
- 2. Su H, Lei CT, Zhang C (2017) Interleukin-6 signaling pathway and its role in kidney disease: an update. Front Immunol 8:405
- Biswas P, Delfanti F, Bernasconi S (1998) Interleukin-6 induces monocyte chemotactic protein-1 in peripheral blood mononuclear cells and in the U937 cell line. Blood 91:258–265
- Beatriz S, Amir S, Victoria C et al (2022) Serum interleukin-6 levels predict kidney disease progression in diabetic nephropathy. Clin Nephro 97(1):1–9
- Mehmet Z, Gulali A, Tuba T et al (2020) Monocyte lymphocyte ratio As a predictor of diabetic kidney injury in type 2 diabetes mellitus The Madkid Study. J Diabetes Metab Disord. 19(2):997–1002
- Fernández-Alvarez V, Linares Sánchez M, López Alvarez F, et al (2022) Evaluation of intima-media thickness and arterial stiffness as early ultrasound biomarkers of carotid artery atherosclerosis. Cardiology and therapy 11(2):231–247. https://doi.org/10.1007/s40119-022-00261
- Van der Meer IM, de Maat MP, Bots ML, Breteler MM (2002) Inflammatory mediators and cell adhesion molecules as indicators of severity of atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol 22:838–842
- Zeynalova S, Bucksch K, Scholz M et al (2021) Monocyte subtype counts are associated with 10-year cardiovascular disease risk as determined by the Framingham Risk Score among subjects of the LIFE-Adult study. PLoS ONF 16(3):e0247480
- Ivan B, Calógero P, Rina M et al (2008) A practical protocol to measure common carotid artery intima-media thickness Clinics (Sao Paulo). 63(4):515–20
- 10. Lorenz MW, Markus HS, Bots ML et al (2007) Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115:459–467
- 11. Chan YH (2003) Biostatistics102: Quantitative Data Parametric & Nonparametric Tests. Singapore Med J 44(8):391–396
- 12. Chan YH (2003) Biostatistics 103: Qualitative Data –Tests of Independence. Singapore Med J 44(10):498–503
- Chan YH (2003) Biostatistics 104: Correlational Analysis. Singapore Med J 44(12):614–619
- Kocak MZ, Aktas G, Duman TT, Atak BM, Alaca B (2020) Monocyte lymphocyte ratio As a predictor of Diabetic Kidney Injury in type 2 Diabetes mellitus; The MADKID Study. J Diabetes Metab Disord 19(2):997–1002
- Kim DI, Park SH (2013) Sequential signaling cascade of IL-6 and PGC-1alpha is involved in high glucose-induced podocyte loss and growth arrest. Biochem Biophys Res Commun 435:702–707
- Ji M, Lu Y, Zhao C, Gao W, He F, Zhang J et al (2016) C5a induces the synthesis of IL-6 and TNF-alpha in rat glomerular mesangial cells through MAPK signaling pathways. PLoS ONE 11:e0161867
- Papaoikonomou S, Tentolouris N, Tousoulis D, Papadodiannis D, Miliou A, Papageorgiou N et al (2013) The association of the 174G>C polymorphism of interleukin 6 gene with diabetic nephropathy in patients with type 2 diabetes mellitus. J Diabetes Complications 27:576–579
- Pham T T, Nguyen G B, Cuc T N (2020) The role of Serum Interleukine-6 level in type 2 diabetic nephropathy. Research Journal of Biotechnology 19(2):997–1002. https://doi.org/10.1007/s40200-020-00595-0
- Akihiko K, Meir S, Taha S et al (2022) Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes. New Insights From CANVAS. 45(11):2644–2652
- Vaishya GP, Kumar G, V.V., Pandey S.K., (2017) Correlational study of interleukin-6 with albuminuria in type 2 diabetes mellitus. International Journal of Research in Medical Sciences. 7(7):2754–2757

- 21. Schmieder RE, Schrader J, Zidek W et al (2007) Low-grade albuminuria and cardiovascular risk: what is the evidence? Clin Res Cardiol 96:247–257
- 22. Ersin B, Tayyibe S, Gokhan S (2022) The relationship of renal resistive index and carotis intima media thickness in patients with diabetic microalbuminuria. Diabetes Epidemiology and Management 5:100027
- 23. Yu-Quing Jie Li, Chen Ji-Yan et al (2017) The Association of Circulating MiR-29b and Interleukin-6 with Subclinical Atherosclerosis. Cell Physiol Biochem 44(4):1537–1544
- 24. Gong S, Gao X, Xu F, et al (2017) Association of lymphocyte to monocyte ratio with severity of coronary artery disease. Medicine. 44(4):1537–1544. https://doi.org/10.1159/000485649
- SahBandarlvo, Lishoma C, Katelyn Saiki, et al (2021) Relationship between Circulating Inflammatory Monocytes and Cardiovascular Disease Measures of Carotid Intimal Thickness 27(5):441–448

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.